Cargando…

Molecular characterization of low grade and high grade bladder cancer

BACKGROUND: Bladder cancer (BC) is the 9(th) most common cancer diagnosis worldwide. Low grade (LG) represents 70% of all BCs, characterized by recurrence and rare ability (10–15%) to progress to high grade (HG) and invade. The remaining 30% is high grade (HG), fast invasive BC, which is resistant t...

Descripción completa

Detalles Bibliográficos
Autores principales: Apollo, Alessandro, Ortenzi, Valerio, Scatena, Cristian, Zavaglia, Katia, Aretini, Paolo, Lessi, Francesca, Franceschi, Sara, Tomei, Sara, Sepich, Carlo Alberto, Viacava, Paolo, Mazzanti, Chiara Maria, Naccarato, Antonio Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334926/
https://www.ncbi.nlm.nih.gov/pubmed/30650148
http://dx.doi.org/10.1371/journal.pone.0210635
_version_ 1783387811277176832
author Apollo, Alessandro
Ortenzi, Valerio
Scatena, Cristian
Zavaglia, Katia
Aretini, Paolo
Lessi, Francesca
Franceschi, Sara
Tomei, Sara
Sepich, Carlo Alberto
Viacava, Paolo
Mazzanti, Chiara Maria
Naccarato, Antonio Giuseppe
author_facet Apollo, Alessandro
Ortenzi, Valerio
Scatena, Cristian
Zavaglia, Katia
Aretini, Paolo
Lessi, Francesca
Franceschi, Sara
Tomei, Sara
Sepich, Carlo Alberto
Viacava, Paolo
Mazzanti, Chiara Maria
Naccarato, Antonio Giuseppe
author_sort Apollo, Alessandro
collection PubMed
description BACKGROUND: Bladder cancer (BC) is the 9(th) most common cancer diagnosis worldwide. Low grade (LG) represents 70% of all BCs, characterized by recurrence and rare ability (10–15%) to progress to high grade (HG) and invade. The remaining 30% is high grade (HG), fast invasive BC, which is resistant to therapy. Identifying biomarkers for predicting those tumors able to progress is a key goal for patient outcome improvement. This study focuses on the most promising prognostic markers. MATERIALS AND METHODS: TP53 and FGFR3 mutational status, Survivin, CK19, CK20, E-cadherin and CD44 gene expression analysis were performed on 66 BCs. RESULTS: Survivin was found associated to tumor grade (p<0.05). Moreover, Survivin correlated with CD44 in TP53 wild type (p = 0.0242) and FGFR3 wild type (p = 0.0036) tumors. In particular the Survivin-CD44 correlation was associated to HG FGFR3 wild type BCs (p = 0.0045). Unsupervised hierarchical clustering based on gene expression data identified four distinct molecular groups reflecting the patient histology (p = 0.038). CONCLUSION: We suggest Survivin, both as a biomarker associated to G3 BCs but negatively related to TP53 mutational status, and as a potential novel therapeutic target.
format Online
Article
Text
id pubmed-6334926
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-63349262019-01-31 Molecular characterization of low grade and high grade bladder cancer Apollo, Alessandro Ortenzi, Valerio Scatena, Cristian Zavaglia, Katia Aretini, Paolo Lessi, Francesca Franceschi, Sara Tomei, Sara Sepich, Carlo Alberto Viacava, Paolo Mazzanti, Chiara Maria Naccarato, Antonio Giuseppe PLoS One Research Article BACKGROUND: Bladder cancer (BC) is the 9(th) most common cancer diagnosis worldwide. Low grade (LG) represents 70% of all BCs, characterized by recurrence and rare ability (10–15%) to progress to high grade (HG) and invade. The remaining 30% is high grade (HG), fast invasive BC, which is resistant to therapy. Identifying biomarkers for predicting those tumors able to progress is a key goal for patient outcome improvement. This study focuses on the most promising prognostic markers. MATERIALS AND METHODS: TP53 and FGFR3 mutational status, Survivin, CK19, CK20, E-cadherin and CD44 gene expression analysis were performed on 66 BCs. RESULTS: Survivin was found associated to tumor grade (p<0.05). Moreover, Survivin correlated with CD44 in TP53 wild type (p = 0.0242) and FGFR3 wild type (p = 0.0036) tumors. In particular the Survivin-CD44 correlation was associated to HG FGFR3 wild type BCs (p = 0.0045). Unsupervised hierarchical clustering based on gene expression data identified four distinct molecular groups reflecting the patient histology (p = 0.038). CONCLUSION: We suggest Survivin, both as a biomarker associated to G3 BCs but negatively related to TP53 mutational status, and as a potential novel therapeutic target. Public Library of Science 2019-01-16 /pmc/articles/PMC6334926/ /pubmed/30650148 http://dx.doi.org/10.1371/journal.pone.0210635 Text en © 2019 Apollo et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Apollo, Alessandro
Ortenzi, Valerio
Scatena, Cristian
Zavaglia, Katia
Aretini, Paolo
Lessi, Francesca
Franceschi, Sara
Tomei, Sara
Sepich, Carlo Alberto
Viacava, Paolo
Mazzanti, Chiara Maria
Naccarato, Antonio Giuseppe
Molecular characterization of low grade and high grade bladder cancer
title Molecular characterization of low grade and high grade bladder cancer
title_full Molecular characterization of low grade and high grade bladder cancer
title_fullStr Molecular characterization of low grade and high grade bladder cancer
title_full_unstemmed Molecular characterization of low grade and high grade bladder cancer
title_short Molecular characterization of low grade and high grade bladder cancer
title_sort molecular characterization of low grade and high grade bladder cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334926/
https://www.ncbi.nlm.nih.gov/pubmed/30650148
http://dx.doi.org/10.1371/journal.pone.0210635
work_keys_str_mv AT apolloalessandro molecularcharacterizationoflowgradeandhighgradebladdercancer
AT ortenzivalerio molecularcharacterizationoflowgradeandhighgradebladdercancer
AT scatenacristian molecularcharacterizationoflowgradeandhighgradebladdercancer
AT zavagliakatia molecularcharacterizationoflowgradeandhighgradebladdercancer
AT aretinipaolo molecularcharacterizationoflowgradeandhighgradebladdercancer
AT lessifrancesca molecularcharacterizationoflowgradeandhighgradebladdercancer
AT franceschisara molecularcharacterizationoflowgradeandhighgradebladdercancer
AT tomeisara molecularcharacterizationoflowgradeandhighgradebladdercancer
AT sepichcarloalberto molecularcharacterizationoflowgradeandhighgradebladdercancer
AT viacavapaolo molecularcharacterizationoflowgradeandhighgradebladdercancer
AT mazzantichiaramaria molecularcharacterizationoflowgradeandhighgradebladdercancer
AT naccaratoantoniogiuseppe molecularcharacterizationoflowgradeandhighgradebladdercancer